ALTANA AG Pulls EU Application For Key Drug

BAD HOMBURG, Germany--(BUSINESS WIRE)--Nov. 15, 2005--ALTANA (NYSE:AAA)(FSE:ALT) today announced that it has withdrawn the European Marketing Authorisation Application (MAA) for Daxas(R) (roflumilast). ALTANA Pharma has taken this decision after consulting with the EMEA today. The submission of a new MAA will be pursued, after further clinical data are available. ALTANA Pharma is committed to continue the development of Daxas(R) and will pursue further clinical studies to strengthen the anti-inflammatory product profile and possible market potential of Daxas(R).

MORE ON THIS TOPIC